Investor Presentation

31st October, 2026 BSE Limited National Stock Exchange of India Limited Phiroze JeeJeebhoy Towers, Exchange Plaza, Plot no. C/1, Dalal Street, G Block, Bandra-Kurla Complex Fort, Mumbai – 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543318 Trading Symbol: CLEAN Subject: Investor Presentation for Quarter and Half Year ended 30th September, 2026 Dear Sir/Madam In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Financial Results presentation for Quarter and Half Year ended 30th September, 2026 is enclosed. The aforesaid presentation is also available on the Company’s website. You are requested to take the same on record. Thanking You. For Clean Science and Technology Limited Ruchita Vij Company Secretary and Compliance Officer Encl: As above Clean Science and Technology Ltd. Investor Presentation Q2 FY 2027 I October 2026 SAFE HARBOUR This investor presentation has been prepared by Clean Science and Technology Limited (“CSTL”) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not be deemed to constitute an offer. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be “forward-looking statements”, including those relating to the general business plans and strategy of Clean Science and Technology , its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as ‘will’, ‘expected to’, ‘horizons of growth’, ‘strong growth prospects’, among many others, or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. Clean Science and Technology Limited may alter, modify, or otherwise change in any manner, the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner. Q2 FY 2027 Business Update Q2 FY2027 UPDATE - Consolidated Progressive revenue growth supported by new segment, margins moderated due to geopolitical headwinds Revenue in INR Crore 241 264 243 245 220 249 268 299 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 41.5% 40.9% 41.6% 40.1% 39.9% 38.9% 39.7% 43.3% 37.1% 37.4% 36.4% 37.0% 36.5% 35.0% 33.4% 31.2% 12.8% 12.9% 10.3% 10.9% 10.7% 11.4% 9.1% 9.2% Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Note: RM - raw material; P&F – power & fuel P&F costs % RM costs % EBITDA % ➢ Incurred total capex of ~ Rs. 150 crores during H1 FY2027 towards investment in Clean Fino Chem Ltd. (CFCL), wholly owned subsidiary of CSTL CAPEX & ➢ CFCL completed advanced HALS product trials with Geneus Chem AG, meeting quality and regulatory standards; commercial launch expected in H2 FY2026–27 BUSINESS UPDATE ➢ Performance Chemical 2, expected to commercialised in H2 FY 27. Q2 FY2027 P&L OVERVIEW Core business strong, new business scaling: CFCL adds INR ~48 crs of YoY sales and turns PAT positive P&L (INR Crore) STANDALONE CONSOLIDATED Particular Q2 FY2027 Q1 FY2027 Q-o-Q (%) Q2 FY2026 Y-o-Y (%) Q2 FY2027 Q1 FY2026 Q-o-Q (%) Q2 FY2026 Y-o-Y (%) Sale of products 226 203 11% 206 10% 295 264 12% 240 23% Other operating income 7 4 5 4 4 5 Total Revenue 233 207 12% 211 10% 299 268 12% 245 22% Raw material expenses 93 70 32% 72 30% 128 105 22% 96 33% Raw material % 41.2% 34.6% 34.7% 43.3% 39.7% 40.1% Other operating expenses 58 50 16% 50 16% 80 67 19% 61 31% EBITDA 82 87 (5%) 90 (9%) 92 96 (5%) 87 5% EBITDA % 36.3% 42.7% 43.6% 31.2% 36.5% 36.4% Depreciation expenses 11 11 11 21 21 19 Finance costs 1 0 0 2 0 0 Other Income 4 21 7 6 22 7 Profit before tax (PBT) 74 97 (24%) 86 (14%) 74 98 (24%) 75 (1%) PBT % 32.7% 48.0% 41.6% 25.2% 36.9% 31.3% Profit after tax (PAT) 55 73 (25%) 65 (14%) 56 73 (25%) 55 0.5% PAT % 24.5% 36.0% 31.3% 18.9% 27.8% 23.2% H1 FY2027 P&L OVERVIEW Stronger growth coming from newer segments, contributing to 22% of the revenue during the first half of the year P&L (INR Crore) STANDALONE CONSOLIDATED Particular H1FY2027 H1FY2026 Y-o-Y (%) H1 FY2027 H1 FY2026 Y-o-Y (%) Sale of products 430 423 2% 559 480 17% Other operating income 10 8 9 8 Total Revenue 440 431 2% 568 488 16% Raw material expenses 164 142 15% 233 180 29% Raw material % 38.1% 33.6% 41.7% 37.5% Other operating expenses 107 99 8% 147 121 21% EBITDA 169 191 (11)% 188 187 1% EBITDA % 39.3% 45.1% 33.7% 39.0% Depreciation expenses 21 22 42 37 Finance costs 2 0 2 0 Other Income 25 20 28 20 Profit before tax (PBT) 171 188 (9)% 172 169 2% PBT % 39.9% 44.5% 30.7% 35.3% Profit after tax (PAT) 129 141 (9)% 129 125 3% PAT% 29.9% 33.3% 23.1% 26.2% H1 FY2027 BALANCE SHEET OVERVIEW Balance sheet shifting from investment phase to asset monitisation phase Standalone Balance Sheet As at As at Consolidated Balance Sheet As at As at (INR Crore) 30-Sept.-2026 31-March-2026 (INR Crore) 30-Sept.-2026 31-March-2026 Assets Assets Non-current assets Non-current assets Fixed Assets 317 336 Fixed Assets 701 719 Capital work-in-progress 11 4 Capital work-in-progress 156 118 Right of use asset 4 4 Right of use asset 35 35 Other non-current assets 953 814 Other non-current assets 74 82 Total non-current assets 1,284 1,157 Total non-current assets 967 955 Current assets Current assets Inventories 142 102 Inventories 221 154 Investments 265 343 Investments 350 347 Trade receivables 190 149 Trade receivables 263 206 Cash and bank balances 8 17 Cash and bank balances 20 28 Other current assets 31 15 Other current assets 99 93 Total current assets Total current assets 635 627 953 828 Total assets 1,919 1,784 Total assets 1,920 1,783 Equity and Liabilities Equity and Liabilities Net-worth 1,733 1,646 Net-worth 1,672 1,584 Non-current liabilities Non-current liabilities Lease liabilities 1 1 Lease liabilities 2 2 Other financial liabilities 2 2 Other financial liabilities 2 2 Other non-current liabilities 31 30 Other non-current liabilities 31 30 Total non-current liabilities 34 33 Total non-current liabilities 35 34 Current liabilities Current liabilities Trade payables 112 74 Trade payables 163 116 Other current liabilities 39 31 Other current liabilities 50 49 Total current liabilities 152 106 Total current liabilities 213 165 Total equity and liabilities 1,919 1,784 Total equity and liabilities 1,920 1,783 REVENUE PROFILE –H1 FY 2027 - Consolidated Performance segment share increased led by higher volume of HALS series REVENUE MIX BY SEGMENT H1 FY’27 H1 FY’26 Performance chemicals Pharma & Agro FMCG chemicals Intermediates ➢ HALS segment grew 2x during the H1 FY27 on the bank of higher volumes. Business Update ➢ Successfully de-risked product concentration, with the top four legacy products' contribution declining from ~85% in Q4 FY23 to ~58% this quarter; HALS now accounts for 22% of sales Corporate presentation CLEAN SCIENCE AND TECHNOLOGY AT A GLANCE A brief Introduction about the Company ➢One of the fastest growing and among the most profitable fine and specialty chemical companies globally. Among the largest manufacturers of certain specialty chemicals developed in-house. ➢Among the few global organizations focused on developing ingenious technologies with unique, innovative, sustainable, and cost- effective catalytic manufacturing processes 500+ 1,600 [Showing first 8,000 characters — download PDF for full document]